Netherlands' Qiagen agrees EUR 10.8 bln EQT buyout; suspends FY 2026 outlook

Overview

• Netherlands molecular diagnostics firm reports preliminary Q3 sales and adjusted EPS

• Company enters business combination agreement with EQT Private Equity, valuing Qiagen at EUR 10.8 bln

• Full-year 2026 outlook suspended due to pending transaction

Outlook

• Company has suspended its full-year 2026 outlook while the EQT transaction is pending

Result Drivers

• TRANSACTION IMPACT - Qiagen suspended its full-year 2026 outlook due to pending business combination agreement with EQT Private Equity

Company press release:

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", 7 "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the biotechnology & medical research peer group is "buy"

• Wall Street's median 12-month price target for QIAGEN N.V. is €42.00, about 1.9% below its October 21 closing price of €42.82

• The stock recently traded at 17 times the next 12-month earnings vs. a P/E of 16 three months ago

Reuters Recommended Reads

• Oct 19 - Germany's Merck buys Silence Therapeutics in $1.3 billion RNA drug deal

• Oct 19 - KKR charged with misleading EU regulators over Telecom Italia network deal

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)